The upgraded role of HER3 and HER4 receptors in breast cancer

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 2, 2010, Pages 73-78

  Koutras, Angelos K ^a   Fountzilas, George ^b   Kalogeras, Konstantine T ^b,c   Starakis, Ioannis ^a   Iconomou, Gregoris ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Breast cancer; HER3; HER4

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL;

EID: 77950074588     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.04.011     Document Type: Review

References (49)

1. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp Cell Res 2003, 284:2-13.
2. Mosesson Y., Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004, 14:262-270.
3. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
4. Karamouzis M.V., Badra F.A., Papavassiliou A.G. Breast cancer: The upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007, 39:851-856.
5. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994, 13:2831-2841.
6. Soltoff S.P., Carraway K.L., Prigent S.A., Gullick W.G., Cantley L.C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994, 14:3550-3558.
7. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
8. Stern D.F. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223.
9. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65.
10. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938.
11. Naidu R., Yadav M., Nair S., Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998, 78:1385-1390.
12. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765.
13. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.
14. Sassen A., Rochon J., Wild P.J., et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3, and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10:R2. [Epub 2008 Jan 8].
15. Lemoine N.R., Barnes D.M., Hollywood D.P., et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992, 66:1116-1121.
16. Gasparini G., Gullick W.J., Maluta S., et al. C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma. An immunocytochemical study. Eur J Cancer 1994, 30A:16-22.
17. Quinn C.M., Ostrowski J.L., Lane S.A., Loney D.P., Teasdale J., Benson F.A. C-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 1994, 25:247-252.
18. Travis A., Pinder S.E., Robertson J.F.R., et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996, 74:229-233.
19. Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6:4217-4225.
20. Lee Y., Cho S., Seo J.H., et al. Correlated expression of erbB-3 with hormone receptor expression and favourable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol 2007, 128:1041-1049.
21. Koutras A.K., Kalogeras K.T., Dimopoulos M.-A., et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer. Br J Cancer 2008, 99:1775-1785. [Epub 2008 Nov 4].
22. Lee H., Akita R.W., Sliwkowski M.X., Maihle N.J. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 2001, 61:4467-4473.
23. Offterdinger M., Schöfer C., Weipoltshammer K., Grunt T.W. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002, 157:929-939.
24. Liu B., Ordonez-Ercan D., Fan Z., Edgerton S.M., Yang X., Thor A.D. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882.
25. Petrelli F., Cabiddu M., Cazzaniga M.E., Cremonesi M., Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 2008, 13:373-381.
26. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
27. Menendez J.A., Lupu R. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?. Breast Cancer Res 2007, 9:111.
28. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97:453-457.
29. Smith B.L., Chin D., Maltzman W., Crosby K., Hortobagyi G.N., Bacus S.S. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004, 91:1190-1194.
30. Narayan M., Wilken J.A., Harris L.N., Baron A.T., Kimbler K.D., Maihle N.J. Trastuzumab-induced HER reprogramming in " resistant" breast carcinoma cells. Cancer Res 2009, 69:2191-2194. [Epub 2009 Mar 10].
31. Sartor C.I., Zhou H., Kozlowska E., et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21:4265-4275.
32. Naresh A., Long W., Vidal G.A., et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006, 66:6412-6420.
33. Barnes N.L., Khavari S., Boland G.P., Cramer A., Knox W.F., Bundred N.J. Absence of HER-4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005, 11:2163-2168.
34. Kainulainen V., Sundvall M., Määttä J.A., Santiestevan E., Klagsbrun M., Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000, 275:8641-8649.
35. Rio C., Buxbaum J.D., Peschon J.J., Corfas G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 2000, 275:10379-10387.
36. Ni C.Y., Murphy M.P., Golde T.E., Carpenter G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294:2179-2181.
37. Jones F.E. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:247-258.
38. Zhu Y., Sullivan L.L., Nair S.S., et al. Coregulation of estrogen receptor by estrogen-inducible ERBB4/HER4 establishes a growth promoting autocrine signal in breast cancer. Cancer Res 2006, 66:7991-7998.
39. Knowlden J.M., Gee J.M., Seery L.T., et al. c-erbB-3 and c-erbB-4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998, 17:1949-1957.
40. Tang C.K., Concepcion X.Z., Milan M., Gong X., Montgomery E., Lippman M.E. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999, 59:5315-5322.
41. Kew T.Y., Bell J.A., Pinder S.E., et al. C-erbB-4 protein expression in human breast cancer. Br J Cancer 2000, 82:1163-1170.
42. Suo Z., Risberg B., Kalsson M.G., et al. EGFR family expression in breast carcinomas. C-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25.
43. Zaczek A., Wełnicka-Jaśkiewicz M., Bielawski K.P., et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol 2008, 134:271-279.
44. Aubele M., Auer G., Walch A.K., et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007, 96:801-807.
45. Junttila T.T., Sundvall M., Lundin M., et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005, 65:1384-1393.
46. Naresh A., Thor A.D., Edgerton S.M., Torkko K.C., Kumar R., Jones F.E. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 2008, 68:6387-6395.
47. Koutras A.K., Evans T.R.J. The epidermal growth factor receptor family in breast cancer. OncoTargets Ther 2008, 1:5-19.
48. Srinivasan R., Poulsom R., Hurst H.C., Gullick W.J. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998, 185:236-245.
49. Walker R.A., Dearing S.J. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53:167-176.